Targetable Alterations in Adult Patients With Soft-Tissue Sarcomas

Abstract

Up to 41% of STS harbored at least 1 clinically relevant GA with potential to influence and personalize therapy. Comprehensive genomic profiling can identify novel treatment paradigms to address the limited options and poor prognoses of patients with STS.